Impact of novel glucose‐lowering therapies on physical function in people with type 2 diabetes: A systematic review and meta‐analysis of randomised placebo‐controlled trials
Pooled result · Self-reported physical function (pooled)Result — go to the resultImprovement 0.12 points CI 0.07–017Authors' conclusion
GLP-1RAs showed improvements in self-reported outcomes of physical function. However, there is limited evidence to draw definitive conclusions especially because of lack of studies exploring the impact of SGLT2i and DPP4i on physical function. There is a need for dedicated trials to establish the association between novel agents and physical function.
Study context
- Population
- People with T2D in randomised placebo-controlled trials; searches 1 April 2005 to 20 January 202211 studies
- Comparison
- Novel glucose-lowering therapies vs placebo
- Outcome
- Change in physical function, novel glucose-lowering therapy vs placebo
- Follow-up
- Trial end-point
Methodological detailsEleven studies: nine GLP-1 RA, one SGLT2i, one DPP-4i
- Eleven studies: nine GLP-1 RA, one SGLT2i, one DPP-4i
Pooled result
Self-reported physical function (pooled)
Improvement
0.12 points
CI 0.07–017
As reported in the abstract
Further pooled results
| Outcome | ETD (CI) | |
|---|---|---|
| SF-36 physical functionIn favour of novel GLTs; all GLP-1 RA | 0.86 (0.28–1.45) | |
| IWQOL-LITE physical functionIn favour of novel GLTs; all except one GLP-1 RA | 3.72 (2.30–5.15) | |
| −50510Difference (linear scale) |
Objective physical function (VO2max, 6MWT)
- No significant between-group differences between intervention and placebo
Original publication
Impact of novel glucose‐lowering therapies on physical function in people with type 2 diabetes: A systematic review and meta‐analysis of randomised placebo‐controlled trials. Diabet Med. Published 5 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →